An epigenetic vaccine model active in the prevention and treatment of melanoma

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Nazmul, A Nazmul H ^a   Magner, William J ^a   Tomasi, Thomas B ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA VACCINE; TRICHOSTATIN A; TUMOR CELL VACCINE; CANCER VACCINE; HLA ANTIGEN CLASS 2;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOASSAY; IMMUNOGENICITY; MELANOMA; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; SPLEEN CELL; TUMOR IMMUNITY; ANIMAL; APOPTOSIS; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; PATHOLOGY; SECRETION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CANCER VACCINES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIGENESIS, GENETIC; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERFERON TYPE II; MELANOMA, EXPERIMENTAL; MICE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 39049115955     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-64     Document Type: Article

References (51)

1. Restifo NP Building better vaccines: How apoptotic cell death can induce inflammation and activate innate and adaptive immunity Curr Opin Immunol 2000, 12(5):597-603. 1955758 11007365 10.1016/S0952-7915(00)00148-5
2. Heath WR Carbone FR Cross-presentation, dendritic cells, tolerance and immunity Annu Rev Immunol 2001, 19:47-64. 10.1146/ annurev.immunol.19.1.47 11244030
3. Nowak AK Lake RA Marzo AL Scott B Heath WR Collins EJ Frelinger JA Robinson BW Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells J Immunol 2003, 170(10):4905-4913. 12734333
4. Khan AN Magner WJ Tomasi TB An epigenetically altered tumor cell vaccine Cancer Immunol Immunother 2004, 53(8):748-754. 10.1007/s00262-004-0513-0 14997346
5. Qi L Rojas JM Ostrand-Rosenberg S Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo J Immunol 2000, 165(10):5451-5461. 11067897
6. Knutson KL Disis ML Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Cancer Immunol Immunother 2005, 54(8):721-728. 10.1007/s00262-004-0653-2 16010587
7. Schoenberger SP Jonges LE Mooijaart RJ Hartgers F Toes RE Kast WM Melief CJ Offringa R Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC Cancer Res 1998, 58(14):3094-3100. 9679976
8. Pulaski BA Ostrand-Rosenberg S Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines Cancer Res 1998, 58(7):1486-1493. 9537252
9. Mortara L Castellani P Meazza R Tosi G De Lerma Barbaro A Procopio FA Comes A Zardi L Ferrini S Accolla RS CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory Clin Cancer Res 2006, 12(11 Pt 1):3435-3443. 10.1158/ 1078-0432.CCR-06-0165 16740768
10. Jabrane-Ferrat N Campbell MJ Esserman LJ Peterlin BM Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice Cancer Gene Ther 2006, 13(11):1002-1010. 10.1038/sj.cgt.7700974 16841083
11. Marincola FM Jaffee EM Hicklin DJ Ferrone S Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance Adv Immunol 2000, 74:181-273. 10605607
12. Tomasi TB Magner WJ Khan AN Epigenetic regulation of immune escape genes in cancer Cancer Immunol Immunother 2006, 55(10):1159-1184. 10.1007/ s00262-006-0164-4 16680460
13. Magner WJ Kazim AL Stewart C Romano MA Catalano G Grande C Keiser N Santaniello F Tomasi TB Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors J Immunol 2000, 165(12):7017-7024. 11120829
14. Khan AN Gregorie CJ Tomasi TB A role for chromatin in the regulation of TAP, LMP, Tapasin genes and MHC class I antigen presentation Cancer Immunol Immunother
15. Jenuwein T Allis CD Translating the histone code Science 2001, 293(5532):1074-1080. 10.1126/science.1063127 11498575
16. Mariadason JM Corner GA Augenlicht LH Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer Cancer Res 2000, 60(16):4561-4572. 10969808
17. Marks PA Richon VM Breslow R Rifkind RA Histone deacetylase inhibitors as new cancer drugs Curr Opin Oncol 2001, 13(6):477-483. 10.1097/ 00001622-200111000-00010 11673688
18. Chou SD Khan AN Magner WJ Tomasi TB Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells Int Immunol 2005, 17(11):1483-1494. 10.1093/ intimm/dxh326 16210330
19. Manjili MH Wang XY Chen X Martin T Repasky EA Henderson R Subjeck JR HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice J Immunol 2003, 171(8):4054-4061. 14530326
20. Sotomayor EM Borrello I Rattis FM Cuenca AG Abrams J Staveley-O'Carroll K Levitsky HI Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression Blood 2001, 98(4):1070-1077. 10.1182/blood.V98.4.1070 11493453
21. Lenz LL Butz EA Bevan MJ Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens J Exp Med 2000, 192(8):1135-1142. 10.1084/ jem.192.8.1135 11034603
22. Nonacs RM Witmer-Pack MD Steinman RM Enrichment of dendritic cells by plastic adherence and EA Rosetting Current Protocols in Immunology 1992 3.7.1
23. Grusby MJ Glimcher LH Immune responses in MHC class II-deficient mice Annu Rev Immunol 1995, 13:417-435. 10.1146/annurev.iy.13.040195.002221 7612230
24. Degli-Esposti MA Smyth MJ Close encounters of different kinds: Dendritic cells and NK cells take centre stage Nat Rev Immunol 2005, 5(2):112-124. 10.1038/nri1549 15688039
25. Hamerman JA Ogasawara K Lanier LL NK cells in innate immunity Curr Opin Immunol 2005, 17(1):29-35. 10.1016/j.coi.2004.11.001 15653307
26. Vallera DA Soderling CC Orosz CG Assessment of immunocompetence by limiting dilution analysis in long-term T cell depletion chimeras transplanted across the MHC barrier Transplantation 1985, 40(3):311-316. 10.1097/00007890-198509000-00018 2930921
27. Hargadon KM Brinkman CC Sheasley-O'neill SL Nichols LA Bullock TN Engelhard VH Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes J Immunol 2006, 177(9):6081-6090. 17056534
28. Magner WJ Tomasi TB Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes Mol Immunol 2005, 42(9):1033-1042. 10.1016/j.molimm.2004.09.030 15829293
29. Brady MS Eckels DD Ree SY Schultheiss KE Lee JS MHC class II-mediated antigen presentation by melanoma cells J Immunother Emphasis Tumor Immunol 1996, 19(6):387-397. 9041456
30. Ostrand-Rosenberg S Pulaski BA Clements VK Qi L Pipeling MR Hanyok LA Cell-based vaccines for the stimulation of immunity to metastatic cancers Immunol Rev 1999, 170:101-114. 10.1111/ j.1600-065X.1999.tb01332.x 10566145
31. Friberg S Mattson S On the growth rates of human malignant tumors: implications for medical decision making J Surg Oncol 1997, 65(4):284-297. 10.1002/ (SICI)1096-9098(199708)65:4<284::AID-JSO11>3.0.CO;2-2 9274795
32. Iezzi G Karjalainen K Lanzavecchia A The duration of antigenic stimulation determines the fate of naive and effector T cells Immunity 1998, 8(1):89-95. 10.1016/S1074-7613(00)80461-6 9462514
33. Obst R van Santen HM Melamed R Kamphorst AO Benoist C Mathis D Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation Proc Natl Acad Sci USA 2007, 104(39):15460-15465. 10.1073/pnas.0707331104 17881563
34. Andreakos E Williams RO Wales J Foxwell BM Feldmann M Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant Proc Natl Acad Sci USA 2006, 103(39):14459-14464. 1599984 16971487 10.1073/pnas.0603493103
35. Gasser S Orsulic S Brown EJ Raulet DH The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor Nature 2005, 436(7054):1186-1190. 1352168 15995699 10.1038/nature03884
36. Ehrlich LI Ogasawara K Hamerman JA Takaki R Zingoni A Allison JP Lanier LL Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells J Immunol 2005, 174(4):1922-1931. 15699119
37. Zhou H Luo Y Lo JF Kaplan CD Mizutani M Mizutani N Lee JD Primus FJ Becker JC Xiang R DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor Proc Natl Acad Sci USA 2005, 102(31):10846-10851. 1182421 16040807 10.1073/pnas.0502208102
38. Kamiryo Y Yajima T Saito K Nishimura H Fushimi T Ohshima Y Tsukamoto Y Naito S Yoshikai Y Soluble branched (1,4)-beta-D-glucans from Acetobacter species enhance antitumor activities against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response Int J Cancer 2005, 115(5):769-776. 10.1002/ijc.20934 15729692
39. Walzer T Dalod M Robbins SH Zitvogel L Vivier E Natural-killer cells and dendritic cells: "l'union fait la force" Blood 2005, 106(7):2252-2258. 10.1182/blood-2005-03-1154 15933055
40. Munz C Steinman RM Fujii S Dendritic cell maturation by innate lymphocytes: Coordinated stimulation of innate and adaptive immunity J Exp Med 2005, 202(2):203-207. 10.1084/jem.20050810 16027234
41. Steinman RM Turley S Mellman I Inaba K The induction of tolerance by dendritic cells that have captured apoptotic cells J Exp Med 2000, 191(3):411-416. 10.1084/jem.191.3.411 10662786
42. Nouri-Shirazi M Banchereau J Bell D Burkeholder S Kraus ET Davoust J Palucka KA Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses J Immunol 2000, 165(7):3797-3803. 11034385
43. Basu S Binder RJ Suto R Anderson KM Srivastava PK Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway Int Immunol 2000, 12(11):1539-1546. 10.1093/intimm/12.11.1539 11058573
44. Inaba K Turley S Yamaide F Iyoda T Mahnke K Inaba M Pack M Subklewe M Sauter B Sheff D Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells J Exp Med 1998, 188(11):2163-2173. 10.1084/ jem.188.11.2163 9841929
45. Albert ML Death-defying immunity: Do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 2004, 4(3):223-231. 10.1038/ nri11308 15039759
46. Roh MS Kim CW Park BS Kim GC Jeong JH Kwon HC Suh DJ Cho KH Yee SB Yoo YH Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells Apoptosis 2004, 9(5):583-589. 10.1023/B:APPT.0000038037.68908.6e 15314286
47. Candido KA Shimizu K McLaughlin JC Kunkel R Fuller JA Redman BG Thomas EK Nickoloff BJ Mule JJ Local administration of dendritic cells inhibits established breast tumor growth: Implications for apoptosis-inducing agents Cancer Res 2001, 61(1):228-236. 11196166
48. Bestor TH Gene silencing. Methylation meets acetylation Nature 1998, 393(6683):311-312. 10.1038/30613 9620794
49. Wischnewski F Pantel K Schwarzenbach H Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells Mol Cancer Res 2006, 4(5):339-349. 10.1158/ 1541-7786.MCR-05-0229 16687489
50. Luo W Wang X Kageshita T Wakasugi S Karpf AR Ferrone S Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells Oncogene 2006, 25(20):2873-2884. 10.1038/sj.onc.1209319 16407841
51. Yu C Friday BB Lai JP McCollum A Atadja P Roberts LR Adjei AA Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation Clin Cancer Res 2007, 13(4):1140-1148. 10.1158/ 1078-0432.CCR-06-1751 17317822